Feature | February 01, 2012| Dave Fornell

Cardiac Technology Trend Predictions for 2012

Based on my observations and those of the doctors on the Diagnostic & Interventional Cardiology Editorial Advisory Board, we created the following list of predictions of what will be hot trends to watch in 2012.

•  FFR-CT: A potential “game-changer” technology that was recently introduced is fractional flow reserve computed tomography (FFR-CT), which  computationally models coronary blood flow, pressure and physiology from static typically acquired by CT scans.  The information may be able to determine if a specific stenosis needs to be stented without the need for invasive, catheter FFR measurements in the cath lab.

•  Transcatheter Heart Valves: With the U.S. Food and Drug Administration (FDA) clearance of the Edwards Sapien valve (see story on Page 34), transcatheter aortic valve implantation (TAVI) is taking center stage at several conferences. Also in FDA trials are Medtronic’s CoreValve aortic valve and Abbott’s MitraClip device for mitral valve repair.

• Percutaneous Renal Nerve Ablation: Medtronic purchased Ardian, which developed the Symplicity renal nerve ablation catheter currently in FDA trial. Data so far has shown the therapy may greatly reduce drug-resistant hypertension.

• Left Atrial Appendage (LAA) Occluders:  These transcatheter occluders are designed to prevent atrial fibrillation-induced emboli and replace the current standard of warfarin therapy. In 2011 the CoHerex WaveCrest entered first-in-man trials and Boston Scientific purchased Atritech’s Watchman LAA occluder.

• Drug-Eluting Balloons: Several DEBs are already available in Europe and several vendors are seeking FDA clearance. Lutonix (purchased by C.R. Bard in December) has an ongoing FDA trial. Medrad, Cook and Medtronic/Invatec are working with the FDA to begin U.S. trials.

• Hybrid Operating Rooms: While hybrid ORs are not a new concept, the approval of the first transcatheter aortic valve and increasingly more complex minimally invasive surgeries and interventional procedures are driving their adoption. Vendors are increasingly emphasizing the hybrid OR applications of their products due to rising interest.

• Robotics in the Cath Lab: The Corindus CorPath 200 cath lab robotic system entered its FDA pivotal clinical trial with possible final review in 2012. Boston Scientific and Philips both partnered with robotic system vendors for closer integration. Hansen Medical is also developing a peripheral artery disease interventional robotic system it hopes will be reviewed in 2012 by the FDA. See the story on Page 8.

I am always interested in hearing readers’ thoughts on technologies or trial data from the past year, or in their predictions for what technologies to watch in the coming year.

Related Content

bioresorbable stents, bioabsorbable stents, visualizing the Absorb BVS, dissolving stent, disappearing stent on IVUS and OCT

A comparison of how the Abbott Absorb BVS appears with intravascular ultrasound (IVUS) on the left, and optical coherence tomography (OCT) of the right. The stent is difficult to visualize and sizing is critical, so both modalities can help in bioresorbable stent measurements and to confirm stent apposition. Left image from the Volcano IVUS system and the right image from St. Jude Medical's OCT system


Feature | Stents Bioresorbable| October 20, 2016 | Dave Fornell
There has been a lot of interest in the interventional community regarding the Abbott Absorb Bioresorbable Vascular S
Toshiba CT, picking a CT scanner, choosing a CT scanner, CT 101, what to look for in CT scanners, Aquilion ONE ViSION

The Toshiba Aquilion One Vision system is among the new generation of CT systems on the market that offers several dose lowering technologies and a hardware/software combination to enhance image quality over previous-generation scanners.

Feature | CT Angiography (CTA)| October 14, 2016 | Dave Fornell
As hospitals begin replacing their first-generation 64-slice computed tomography (CT) scanners after a decade of use,
SentreHeart, Eclipse Surgical Device, left atrial appendage, LAA closure, first clinical use, Poland
News | Left Atrial Appendage (LAA) Occluders| October 13, 2016
SentreHeart Inc. announced this week it has treated the first patients using the Eclipse Surgical Device, which is...
Cardioband, first tricuspid valve repair, University Hospital Zurich, Francesco Maisano
News | Heart Valve Technology| October 10, 2016
Francesco Maisano, clinic director at the University Hospital Zurich, recently led a team of cardiac surgeons and...
St. Jude Medical, PressureWire X Guidewire, FDA, launch, FFR catheter
Technology | FFR Catheters| October 10, 2016
St. Jude Medical Inc. announced the U.S. clearance and launch of the company’s new PressureWire X Guidewire fractional...
Northwestern Medicine, Edwards Lifesciences, Intuity Elite suturless aortic valve, first in Illinois

Edwards Intuity valve image courtesy of Northwestern Medicine

News | Heart Valve Technology| October 07, 2016
October 7, 2016 — A Northwestern Medicine cardiac surgeon was recently the first in Illinois and second in the United
Xeltis bioabsorbable valve implant, two-year data, EACTS 2016
News | Heart Valve Technology| October 06, 2016
October 6, 2016 — Xeltis announced this week that patients...
Xeltis bioabsorbable pulmonary heart valve, Xplore-I clinical feasibility study, first pediatric implants, EACTS 2016
News | Heart Valve Technology| October 04, 2016
October 4, 2016 — Xeltis recently announced that three pediatric patients have been successfully implanted with the w
Sponsored Content | Videos | Congenital Heart| October 04, 2016
Xeltis, a Swiss-Dutch clinical-stage medical device company, recently implanted three pediatric patients with the wor
Overlay Init